(VIANEWS) – TG Therapeutics (TGTX), California Resources Corporation (CRC), Global Self Storage (SELF) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. TG Therapeutics (TGTX)
224.1% sales growth and 11.57% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.09.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 171.56. Meaning, the purchaser of the share is investing $171.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.57%.
Sales Growth
TG Therapeutics’s sales growth is 599.5% for the ongoing quarter and 224.1% for the next.
Moving Average
TG Therapeutics’s worth is below its 50-day moving average of $15.53 and higher than its 200-day moving average of $14.63.
Yearly Top and Bottom Value
TG Therapeutics’s stock is valued at $15.44 at 06:22 EST, way below its 52-week high of $35.67 and way higher than its 52-week low of $6.46.
2. California Resources Corporation (CRC)
22.4% sales growth and 27.63% return on equity
California Resources Corporation operates as an independent oil and natural gas company committed to energy transition in the sector. It has carbon intensity production in the United States, as well as focuses on developing carbon capture and storage (CCS) and other emissions reducing projects. The company explores for, produces, gathers, processes, and markets crude oil, natural gas, and natural gas liquids for marketers, California refineries, and other purchasers that have access to transportation and storage facilities. It holds interests in approximately 2.1 million net mineral acres covering four oil and gas basins. As of December 31, 2020, the company had proved reserves of 442 million barrels of oil equivalent. It also engages in the generation and sale of electricity to the local utility, other third parties, and the grid. The company was incorporated in 2014 and is based in Santa Clarita, California.
Earnings Per Share
As for profitability, California Resources Corporation has a trailing twelve months EPS of $7.78.
PE Ratio
California Resources Corporation has a trailing twelve months price to earnings ratio of 6.94. Meaning, the purchaser of the share is investing $6.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.63%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
California Resources Corporation’s EBITDA is 1.37.
3. Global Self Storage (SELF)
10.7% sales growth and 4.73% return on equity
Global Self Storage is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. Through its wholly owned subsidiaries, the company owns and/or manages 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Earnings Per Share
As for profitability, Global Self Storage has a trailing twelve months EPS of $0.2.
PE Ratio
Global Self Storage has a trailing twelve months price to earnings ratio of 21. Meaning, the purchaser of the share is investing $21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.73%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Global Self Storage’s EBITDA is 69.58.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 12.27M for the twelve trailing months.
Moving Average
Global Self Storage’s worth is under its 50-day moving average of $4.38 and way under its 200-day moving average of $4.74.
4. Halozyme Therapeutics (HALO)
8.8% sales growth and 222.07% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.1.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 19.09. Meaning, the purchaser of the share is investing $19.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 222.07%.
Volume
Today’s last reported volume for Halozyme Therapeutics is 791827 which is 41.96% below its average volume of 1364310.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Halozyme Therapeutics’s EBITDA is 7.54.
Previous days news about Halozyme Therapeutics(HALO)
- According to Zacks on Thursday, 28 March, "Over the past month, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , a stock from the same industry, has gained 2.6%. "
- According to Zacks on Friday, 29 March, "Over the past month, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , a stock from the same industry, has gained 2.2%. "
5. First Business Financial Services (FBIZ)
7.7% sales growth and 13.46% return on equity
First Business Financial Services, Inc. operates as the bank holding company for First Business Bank that provides commercial banking products and services for small and medium-sized businesses, business owners, executives, professionals, and high net worth individuals. The company offers deposit products, such as non-interest-bearing transaction accounts, interest-bearing transaction accounts, money market accounts, time deposits, and certificates of deposit, as well as credit cards. It also provides loan products, including commercial real estate loans, commercial and industrial loans, small business administration loans, and direct financing leases, as well as consumer and other loans comprising home equity, first and second mortgage, and other personal loans for professional and executive clients. The company offers commercial lending, asset-based lending, equipment financing, accounts receivable financing, vendor financing, floorplan financing, treasury management services, and company retirement plans; trust and estate administration, financial planning, investment management, and private banking services; and investment portfolio administrative, asset-liability management, and asset-liability management process validation services for other financial institutions. First Business Financial Services, Inc. was founded in 1909 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, First Business Financial Services has a trailing twelve months EPS of $4.33.
PE Ratio
First Business Financial Services has a trailing twelve months price to earnings ratio of 8.04. Meaning, the purchaser of the share is investing $8.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.46%.
Moving Average
First Business Financial Services’s value is under its 50-day moving average of $35.60 and above its 200-day moving average of $33.35.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 6.7% and 15.3%, respectively.
6. Regional Management Corp. (RM)
7.1% sales growth and 5.06% return on equity
Regional Management Corp., a diversified consumer finance company, provides various installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders in the United States. It offers small and large installment loans; and retail loans to finance the purchase of furniture, appliances, and other retail products. The company also provides insurance products, including credit life, credit accident and health, credit property, vehicle single interest, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. In addition, its loans are sourced through branches, centrally managed direct mail campaigns, digital partners, and retailers, as well as its consumer website. As of February 24, 2022, the company operated through a network of approximately 350 branches in 14 states. Regional Management Corp. was incorporated in 1987 and is headquartered in Greer, South Carolina.
Earnings Per Share
As for profitability, Regional Management Corp. has a trailing twelve months EPS of $1.66.
PE Ratio
Regional Management Corp. has a trailing twelve months price to earnings ratio of 13.98. Meaning, the purchaser of the share is investing $13.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7%, now sitting on 534.23M for the twelve trailing months.
Yearly Top and Bottom Value
Regional Management Corp.’s stock is valued at $23.20 at 06:22 EST, way below its 52-week high of $34.60 and way higher than its 52-week low of $20.50.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Feb 21, 2024, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 5.17%.
Sales Growth
Regional Management Corp.’s sales growth is 3.5% for the current quarter and 7.1% for the next.
7. CubeSmart (CUBE)
5.2% sales growth and 14.27% return on equity
CubeSmart is a self-administered and self-managed real estate investment trust. The Company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. According to the 2020 Self-Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the United States.
Earnings Per Share
As for profitability, CubeSmart has a trailing twelve months EPS of $1.82.
PE Ratio
CubeSmart has a trailing twelve months price to earnings ratio of 23.51. Meaning, the purchaser of the share is investing $23.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.27%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CubeSmart’s EBITDA is 65.41.
